Damian Fukuyama
This study aims to investigate the potential role of enhancing L-Aminoisobutyric Acid (LAIBA) in the pathophysiology of Treatment-Resistant Schizophrenia (TRS) and its effect on the adverse effects of clozapine. TRS is a challenging form of schizophrenia characterized by a lack of response to conventional antipsychotic medications, including clozapine, which is often prescribed as a last resort. Recent evidence suggests that alterations in neurotransmitter systems, including glutamatergic dysfunction, may contribute to TRS. LAIBA, a non-proteinogenic amino acid, has been shown to modulate glutamatergic transmission. In this study, we investigated the effects of LAIBA on TRS and the adverse effects associated with clozapine treatment in an animal model. Our findings suggest that enhancing LAIBA levels may have therapeutic potential in TRS by regulating glutamatergic signaling and ameliorating the adverse effects of clozapine. Further research is warranted to explore the underlying mechanisms and evaluate the translational potential of LAIBA supplementation in TRS.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 